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Abstract
Genome-wide association studies (GWAS) are routinely conducted for both quantitative and binary (disease) traits. We
present two analytical tools for use in the experimental design of GWAS. Firstly, we present power calculations quantifying
power in a unified framework for a range of scenarios. In this context we consider the utility of quantitative scores (e.g.
endophenotypes) that may be available on cases only or both cases and controls. Secondly, we consider, the accuracy of
prediction of genetic risk from genome-wide SNPs and derive an expression for genomic prediction accuracy using a liability
threshold model for disease traits in a case-control design. The expected values based on our derived equations for both
power and prediction accuracy agree well with observed estimates from simulations.
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Introduction
In the last five years, GWAS have been published for both
quantitative traits (such as height [1], or blood markers [2]) and
disease [3]. In order to assess the relative potential for success of
these studies Yang et al. [4] provided an analytical method for
comparison of power. For example, this method has been used to
quantify that a sample of ,50,000 schizophrenia cases and 50,000
controls is needed to afford the same power as the largest
published GWAS of height (a total sample size of 180,000) [5].
Use of quantitative endophenotypes rather than binary traits
has been proposed as a strategy to increase power in neuropsy-
chiatric disorders [6]. Endophenotypes are measurable quantita-
tive scores that are assumed to be associated with a continuous
liability that underlies observed disease status, in which case the
quantitative score may be more informative and powerful
compared to binary responses. Of course, the true underlying
liability would be the most informative although it is not
observable. Recently, van der Sluis et al. [7] suggested a better
use of phenotypic information in GWAS of psychiatric disorders
measured in population cohorts. Rather than using binary
responses of affected/non-affected they considered the use of
continuous scores from diagnostic instruments. They showed that
binary responses based on clinical cut-off criteria decreased power
dramatically compared to the use of sum scores of item responses
from the diagnostic instrument. The authors recommended that
continuous quantitative responses such as sum scores of item
responses should be used in psychiatry disorder GWAS, where
possible. The study by van der Sluis et al. [7] compared scenarios
by simulation and was based on population samples. Here, we
provide an analytical method to calculate power in different
scenarios with both population and case control samples.
Another potential use of data collected in GWAS is the
prediction of genetic risk. Genomic-enabled prediction is a
potentially powerful tool to identify individuals at higher risk of
disease [3,8]. Undoubtedly, prediction accuracy plays a crucial
role in a successful clinical application for genetic risk prediction of
disease, and several studies have evaluated the predictive ability
[9,10,11]. Daetwyler et al. [12] derived a theoretical accuracy for
predicting genetic risk from genome-wide SNPs, based on least
squares methodology. Many studies have used their formula,
which works well for quantitative traits. However, in simulation
studies their formula for case-control traits underpredicted the true
accuracy (Table 4 of Daetwyler et al. [12]).
In this study, we address two issues relevant for the design case-
control GWAS, power and genomic prediction accuracy. First, we
derive analytically, in a unified framework, the power of GWAS
when using population or ascertained case-control samples with
binary as well as quantitative responses. Secondly, we derive
genomic prediction accuracy based on the 0,1 observed scale, and
transform it to the liability scale using a liability threshold model
for disease traits in population [13] and in case-control samples
[14]. The expected values based on our derived equations and the
average of observed estimates from simulation agree well.
Materials and Methods
Power
Given a specified critical value for significance, power of a given
association study design can be derived from the non-centrality
parameter (NCP, l) of a x2 test of association. Following methods
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of Yang et al. [4] we derive the NCP for five different
experimental designs:, i.e. quantitative responses in population
(QT_POP) (1), binary responses in population (BT_POP) (2),
binary responses in ascertained case-control samples (BT_CC) (3),
quantitative responses in ascertained case-control samples
(QT_CC) (4) and samples of both ascertained cases and controls
in which quantitative responses are available in the cases only
(QB_CC) (5). The derived NCP for BT_CC, QT_CC and
QB_CC are novel. Following Yang et al. [4],
1) NCP for quantitative responses in population samples, lQT POP
lQT POP~Nh
2=(1{h2) ð1Þ
where N is the total number of sample, h2 is the proportion of
variance explained by a single genetic marker or set of markers, i.e.
multi locus association tests [15,16].
1) NCP for binary traits in population samples
lBT POP~N:h
2
o=(1{h
2
o) ð2Þ
where h2o is the proportion of variance explained by a genetic
marker or set of markers on the observed scale, and h20&z
2h2[13],
where z is the height of the normal curve truncating the
proportion K, where K is the proportion of the population that
are cases.
1) NCP for binary responses in ascertained case-control samples, lBT CC
lBT CC~N:h
2
occ
=(1{h2occ ) ð3Þ
where h2occ&z
2h2P(1{P)=½K(1{K)2h2=s2gcc , [14,17], with
P the proportion of cases in the case control sample and s2gcc
the genetic variance in the case-control sample inflated
relative to the population sample as a result of the
ascertainment process [12], such cases are over-represented
compared to the population sample. When h2 and h2occ is
small, (3) can be approximated and simplified as
lBT CC&N:z2h2P(1{P)=½K(1{K)2, which agrees with
the derivation based on the relative risk and multiplicative
model by Yang et al. [4].
2) NCP for quantitative responses in ascertained case-control samples,
lQT CC
lQT CC~N:h
2
cc=(1{h
2
cc) ð4Þ
where h2cc&s
2
lcc
h4=s2gcc , where s
2
lcc
is the variance of disease
liability [18]. This equality is derived from quantitative
genetic theory [18] in the following way. Firstly,
s2lcc~1{i½(P{K)=(1{K)½if(P{K)=(1{K)g{t ð5Þ
where i is the mean liability in cases and t is the threshold on
the normal distribution which truncates the proportion of
disease prevalence K, and from Daetwyler et al. [12]
s2gcc~h
2½1{h2i½(P{K)=(1{K)½if(P{K)=(1{K)g{t: ð6Þ
In a similar manner, the inflated variance due to non-genetic
effects is,
Table 1. Expected power for an association study from the derived equations and observed averaged power from simulation.
BT_POP BT_CCa QT_POP QT_CCa
h2 Exp Obs (SE) Exp Obs (SE) Exp Obs (SE) Exp Obs (SE)
N= 2000, K= 0.1
0.0001 0.058 0.053 (0.002) 0.072 0.072 (0.003) 0.073 0.075 (0.003) 0.082 0.083 (0.003)
0.0005 0.090 0.086 (0.003) 0.164 0.163 (0.004) 0.170 0.172 (0.004) 0.218 0.221 (0.004)
0.001 0.131 0.130 (0.003) 0.281 0.286(0.005) 0.293 0.294 (0.005) 0.386 0.386 (0.005)
N= 2000, K= 0.01
0.0001 0.052 0.057 (0.002) 0.092 0.092 (0.003) 0.073 0.075 (0.003) 0.105 0.102 (0.003)
0.0005 0.058 0.057 (0.002) 0.270 0.267(0.004) 0.170 0.169 (0.004) 0.333 0.329 (0.005)
0.001 0.067 0.066 (0.002) 0.478 0.474 (0.005) 0.293 0.295 (0.005) 0.579 0.574 (0.005)
N= 2000, K= 0.001
0.0001 0.050 0.042 (0.002) 0.117 0.117(0.003) 0.073 0.075 (0.003) 0.130 0.132 (0.003)
0.0005 0.051 0.052 (0.002) 0.392 0.387 (0.005) 0.170 0.176 (0.004) 0.451 0.451 (0.005)
0.001 0.053 0.052 (0.002) 0.664 0.657 (0.005) 0.293 0.296 (0.005) 0.738 0.733 (0.004)
h2: variance explained by the locus.
a: in case-control samples, 50% of the sample are cases, P = 0.5.
Exp: Expected power based on NCP derived from equation (1),(4).
Obs: Averaged power over 10000 replicates of simulation.
SE: Empirical standard error over 10000 replicates.
doi:10.1371/journal.pone.0071494.t001
3
4
2
Power and Genomic Prediction Accuracy
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e71494
s2ecc~(1{h
2)½1{(1{h2)i½(P{K)=
(1{K)½if(P{K)=(1{K)g{t :
ð7Þ
The covariance between disease liability and genetic values in
an ascertained case-control sample is
cov(lcc,gcc)~cov(gcczecc,gcc)~s
2
gcc
zcov(gcc,ecc)
where cov(gcc,ecc)~(s
2
lcc
{s2gcc{s
2
ecc
)=2.
Therefore, from (5), (6) and (7),
cov(lcc,gcc)~h
2s2lcc
The regression coefficient of lcc on gcc is
b(lcc:gcc)~cov(lcc,gcc)=s
2
gcc
~h2s2lcc=s
2
gcc
Finally, the proportion of variance attributable to the SNPs or
set of SNPs of a quantitative response in an ascertained case-
control sample can be obtained as the squared regression
coefficient multiplied by the genetic variance in the case-control
sample and scaled by the variance of disease liability in the case
control sample, i.e.
h2cc&½b(lcc:gcc)2s2gcc=s2lcc~s2lcch4=s2gcc :
Figure 1. Power derived for QT_POP (dotted line), BT_POP
(solid line), BT_CC (dashed line) and QT_CC (dot-dashed line)
when using population prevalence K=0.1 (a), K=0.01 (b) or
K=0.001 (c) assuming the same total sample size N=2000 and
a critical significance threshold of 561028.
doi:10.1371/journal.pone.0071494.g001
Table 2. Prediction accuracy for a disease with population or
case-control samples when true proportion of variance
explained by the set of SNPs on the liability scale is 0.5, t= N/
M is 1 for different disease prevalences.
Prevalence Population Case-Control
Exp1 Est (se) Exp2 Exp3 Est (se)
0.001 0.075 0.063 (0.004) 0.628 0.766 0.767 (0.002)
0.01 0.186 0.183 (0.003) 0.594 0.689 0.690 (0.002)
0.1 0.382 0.377 (0.003) 0.533 0.568 0.570 (0.002)
0.2 0.444 0.438 (0.003) 0.511 0.526 0.529 (0.003)
0.5 0.491 0.487 (0.003) 0.491 0.491 0.487 (0.003)
Exp1: Expected value from equation (2) or equation (6) of Daetwyler et al.
(2008).
Exp2: Expected value from equation (9) of Daetwyler et al (2008).
Exp3: Expected value from equation (3).
Est: Average of estimates from 100 replicates.
se: Empirical standard error over 100 replicates.
Proportion of cases in case-control study is P = 0.5.
doi:10.1371/journal.pone.0071494.t002
Table 3. Prediction accuracy for a disease with population or
case-control samples when prevalence is 0.01, t= N/M is 1 for
diseases with different h2.
h2 Population Case-Control
Exp1 Est (se) Exp2 Exp3 Est (se)
0.1 0.084 0.087 (0.004) 0.371 0.392 0.395 (0.003)
0.5 0.186 0.183 (0.003) 0.594 0.689 0.690 (0.002)
0.9 0.246 0.243 (0.003) 0.653 0.787 0.787 (0.001)
Exp1: Expected value from equation (2) or equation (6) of Daetwyler et al.
(2008).
Exp2: Expected value from equation (9) of Daetwyler et al (2008).
Exp3: Expected value from equation (3).
Est: Average of estimates from 100 replicates.
se: Empirical standard error over 100 replicates.
Proportion of cases in case-control study is P = 0.5.
doi:10.1371/journal.pone.0071494.t003
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1) NCP for quantitative responses for cases only in ascertained case-control
samples, lQB CC
When underlying continuous quantitative responses are avail-
able only for cases in the ascertained case-control sample, i.e. the
recorded values follow a mixture distribution of zero for controls
and truncated normal distribution for cases. An example may be a
GWAS of major depressive disorder in which cases are recorded
for a quantitative severity score, whereas controls have not been
scored. In this situations,
lQB CC~N:h
2
mcc
=(1{h2mcc ) ð8Þ
where h2mcc&½b(ycc:gcc)2s2gcc=s2ycc , which is explained as follows.
The variance of the mixed zero and truncated normal values in
an ascertained case-control sample is,
s2ycc~P(1zit){P
2i2
where i and t are the same as defined above. There is an
assumption here is that the quantitative trait is the phenotypic
liability.
The covariance between ycc and gcc in an ascertained case-
control sample is,
cov(ycc,gcc)~E(ycc
:gcc){E(ycc)E(gcc)~
PE(ycc
:gccjcase){PE(yccjcase)E(gcc)
where
E(ycc
:gccDcase)~cov(ycc,gccDcase)zE(yccDcase)E(gccDcase),
cov(ycc,gccDcase)~var(gccDcase)zcov(gcc,eccDcase),
and,
cov(gcc,eccDcase)~½var(lccDcase){var(gccDcase){var(eccDcase)=2:
From the equations above, regression coefficient of ycc on gcc
can be derived analytically as,
b(ycc:gcc)~cov(ycc,gcc)=s
2
gcc
:
Therefore, the proportion variance attributable to the variance
in the SNPs from mixed zero and quantitative response in an
ascertained case-control sample (h2mcc ) can be expressed as above
under (8). The power for this mixed 0 and truncated normal
responses is very similar to that for BT_CC (results not shown).
Genomic prediction accuracy
Normal quantitative traits. For a quantitative trait, bj is the
random allelic substitution effect of the jth single nucleotide
polymorphism (SNP). Following Daetwyler et al. [12], prediction
error variance for the jth SNP effect is
var(b^j{bj)~s
2

N:var(xij)
  ð9Þ
where b^j is the estimate of the true regression bj of the phenotype
on the jth SNP genotype, xij = 0, 1 or 2 for the ith individual, N is
the number of individual records and s2 is the residual variance.
Assuming a phenotypic variance of one, the genetic variance
(var(g)) explained by the set of M SNPs is h2. Following Daetwyler
et al. [12], the estimated genetic variance explained by the M
SNPs in the predictor (var(g^)) is a function of the h2, M, the
number of records (N) and the residual variance (s2) as
var(g^)~
XM
j~1
var(xijbj)z
XM
j~1
var(xij):s
2

N:var(xij)
 
~h22z(M:s2)

N
The squared correlation coefficient between the true and
estimated genetic value is the ratio of the true genetic variance
over the estimated genetic variance [12] as
r2g,g^~var(g)=var(g^)~
h2
h2z(M:s2)=N
where the residual variance would be approximated as s2 = 1
(phenotypic variance) as in Daetwyler et al. [12]. With t defined as
the ratio of the number of samples (N) over the number of SNPs
(M), the accuracy can also be written as [12]
r2g,g^~
h2
h2z1=t
:
Disease traits in population sample. In binary disease
traits, with s2 approximated as s2 = K(1–K) (i.e. binomial
phenotypic variance for a disease with population prevalence of
K), the prediction error variance for the jth SNP effect can be
written as
var(b^j{bj)~s
2

N:var(xij)
 
~K(1{K)

N:var(xij)
 
Table 4. Prediction accuracy for a disease with population or
case-control samples when true proportion of variance
explained by the set of SNPs on the liability scale is 0.5,
prevalence is 0.01 and t= N/M varies.
t=N/M Population Case-Control
Exp1 Est (se) Exp2 Exp3 Est (se)
0.02 0.027 0.028 (0.003) 0.104 0.133 0.124 (0.004)
1 0.186 0.183 (0.003) 0.594 0.689 0.690 (0.002)
5 0.390 0.389 (0.004) 0.731 0.905 0.905 (0.001)
Exp1: Expected value from equation (2) or equation (6) of Daetwyler et al.
(2008).
Exp2: Expected value from equation (9) of Daetwyler et al (2008).
Exp3: Expected value from equation (3).
Est: Average of estimates from 100 replicates.
se: Empirical standard error over 100 replicates.
Proportion of cases in case-control study is P = 0.5.
doi:10.1371/journal.pone.0071494.t004
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where b is allele substitution effect on the 0, 1 observed scale and b^
is the estimated b from regression of the 0,1 discrete phenotypes
on SNP coefficients. The estimated genetic variance on the
observed scale of the SNP predictor (var(u^)) is a function of the
genetic variance on the observed scale (var(u) or s2u), the number of
SNPs, the number of records and the residual variance as
var(u^)~
XM
j~1
var(xijbj)z
XM
j~1
var(xij):s
2

N:var(xij)
 
~s2u2z½M:K(1{K)=N:
The squared correlation coefficient between the true and
estimated genetic values is
r2u,u^~var(u)=var(u^)~
s2u
s2u2z½M:K(1{K)=N
~
h2o
h2oz1=t
:
Because genetic variance as a proportion of phenotypic variance
on the observed scale can be transformed from that on the liability
scale as h2o%s
2
u

K(1{K)~h2z2

K(1{K) [13], prediction
accuracy can be re-expressed as
r2u,u^&
h2z2
h2z2zK(1{K)=t
: ð10Þ
Equation (10) here is the same as equation (6) in Daetwyler et al.
[12].
Disease traits in ascertained case-control
study. Ascertainment in case-control samples often results in
over-representation of cases compared to the case prevalence in
the population. The variance of the explanatory variable is inflated
by a factor of f~s2gcc=s
2
g [12,17]. The term, s
2
gcc
, is the inflated
genetic variance due to ascertainment in case-control sample [12].
Therefore, the inflated explanatory variable for the jth SNP can be
written as var(xij)
~var(xij):fj . Then, the prediction error
variance for the jth SNP effect can be expressed as
var(b^j{bj)~s
2

N:var(xij):fj
 
where b is allele substitution effect on the 0, 1 observed scale and b^
is estimated b from regression of the 0,1 discrete phenotypes on
SNP coefficients in the case-control sample. The estimated genetic
variance on the observed scale in a case-control design can be
derived as
var(u^cc)~
XM
j~1
var(xijbj)z
XM
j~1
var(xij):s
2

N:var(xij):fj
 
where var(xijbj) is the genetic variance on the observed scale due to
the jth SNP effect transformed to the liability scale [14,17]
var(xijbj)& z
P(1{P)
K(1{K)
 2s2gj
fj
. With a sufficient number of causal
SNPs (.,20), the residual variance is approximated as s2 = P(1–
P) (i.e. the binomial phenotypic variance in a case-control sample
where the proportion of cases is P), and the value for f is close to 1
(i.e. a small fraction of genetic variance has a negligible inflation).
Therefore, the genetic variance in a case-control sample is
var(ucc)& z
P(1{P)
K(1{K)
 2
s2g
and, the estimated genetic variance in a case-control sample is
approximately
var(u^cc)& z
P(1{P)
K(1{K)
 2
s2g z½M:P(1{P)=N
The squared correlation coefficient between the true and
estimated genetic values is
r2u,u^~var(ucc)=var(u^cc)&
h2z2
h2z2z½K(1{K)2=½t:P(1{P) ð11Þ
Equation (11) differs from equation (9) of Daetwyler et al. [12],
i.e.
h2z2
h2z2z½K(1{K)2:s2gcc=½t:P(1{P):s2g
:
For binary traits, area under the receiver-operator characteristic
curve (AUC) is a useful statistic for the genomic prediction
accuracy [19,20]. A relationship between the correlation coeffi-
cient and AUC has been shown in previous studies [11,20].
Simulation Study
Power
In order to check the analytically derived equations of NCP for
BT_POP, BT_CC, QT_POP and QT_CC, we carried out a
simulation study. Individual genetic values (g) were simulated from
an additive multilocus model of M= 100 independent SNPs with
equal allele effects and allele frequency of 0.5. Residual values (e)
were independently generated from a random normal distribution
with a mean of zero and variance of s2e . The value of s
2
e was set
relative to s2g so that the desired proportion of variance explained
by the markers, h2 was obtained. We simulated h2 of 0.01, 0.05 and
0.1 so that each SNP explained 0.0001, 0.0005 and 0.001 of the
phenotypic variance (Table 1). Liability phenotypes for each
individual were simulated as y = g + e. Affected individuals were
those with liability phenotype that exceeded a threshold
determined by population prevalence. The numbers of cases and
controls in the sample was 2000. The values for population
prevalence were varied as K = 0.1, 0.01 or 0.001. The proportion
of cases was P = K in simulations of population sample and P = 0.5
in simulations of case-control sample where cases were over-
sampled by a factor (1–K)/K. In population or case-control sample,
we used both binary (BT_POP or BT_CC) and quantitative
responses (QT_POP or QT_CC). We conducted 100 replicates for
each simulation scenario, therefore 10000 association tests were
carried out. Power was calculated as the proportion of the 10000
Power and Genomic Prediction Accuracy
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association tests in which the association p-value less than 0.05 and
was compared to power calculated from the NCP using a function
in R package, i.e. power = 1– pchisq (T, 1, ncp = NCP) where T
is the normal distribution threshold corresponding to the
significance level 0.05.
Genomic prediction accuracy
Simulations were carried out to verify the validity of equations
(10) and (11). In a simulation study, individual genetic values (g)
were simulated from an additive multilocus model with equal allele
effects (allele frequency of ,0.5) and residual values (e) indepen-
dently generated from a random normal distribution with a mean
of zero and variance of s2e . The value of s
2
e was set relative to s
2
g so
that the desired proportion of variance explained by the markers,
h2 was obtained. Liability phenotypes for each individual were
simulated as y = g + e. Affected individuals were those with
liability phenotype that exceeded a threshold determined by
population prevalence. Population prevalences of K = 0.001, 0.01,
0.1, 0.2 and 0.5 were used with N = 2000 and M= 2000. To vary
t= N/M, N = 2000 and M= 400 were used for t= 5, and N = 100
and M = 5000 were used for t= 0.02. Following Daetwyler et al.
[12], allele substitution effects (b^) were estimated using a regression
analysis for each simulated SNP. As a validation set, a second
sample of individuals was generated based on the same genetic
parameters as in the original population. Empirical prediction
accuracy can be obtained by correlating the true genetic values (g)
and estimated genetic values g^~
X
1ƒjƒM
xij b^j in the validation set.
Results
Power
The power of association tests observed in simulation and
expected from theory agreed well under a range of scenarios
(Table 1). Whether using lower or higher values of disease
prevalence K, there was an excellent agreement between the
observed and expected power with a small empirical standard
error. When using a higher variance explained by each locus (h2),
although the empirical standard error increased slightly, the
observed value also agreed well with the expected value (Exp and
Obs in Table 1).
In Figure 1, values for the power based on NCP derived from
equations (1),(4) were plotted against variance explained by SNPs
(i.e., h2). Generally, the power increases when the variance
explained by SNPs increases, and when the ascertained case-
control design is used. For BT_POP, the power decreases as K
decreases, reflecting the smaller number of cases in a given
population sample. For QT_POP, the power is, of course,
constant across a–c in Figure 1. When using an ascertained
sample (BT_CC or QT_CC), the power increases as the value for
K decreases, which reflects the greater over-sampling of cases with
lower K for the same sample size and hence the difference in mean
liability between cases and controls increases. There is a moderate
difference between BT_CC and QT_CC when using population
prevalence K = 0.1 (a in Figure 1). The difference between BT_CC
and QT_CC becomes smaller with lower values for K (b and c in
Figure 1).
Genomic prediction accuracy
The expected accuracies predicted from equation (11) agreed
well with the observed average of estimates from simulation for all
simulation scenarios for both population and ascertained case-
control samples. In Table 2, disease prevalence K varies, in Table 3
proportion of variance explained by SNPs h2 varies and in Table 4,
values for t= N/M vary. For comparison, we list also the predicted
accuracies for case-control samples provided in Daetwyler et al.
[12]. As shown in their Table 4, their formula underestimates
prediction accuracy particularly when disease prevalences are low
(Table 2) and h2 are high (Table 3). We also tested the prediction
accuracy with allele effects sampled from a normal or an
exponential distribution. The results from these alternative
distributions of allele effects were not much different from the
main results (results not shown). This agrees with Daetwyler et al.
[12] in that the derived prediction accuracy is robust to
distributional assumption for allele effects.
Discussion
Firstly, we provide analytical derivations in a unified framework
to quantify the power of GWAS when using population or
ascertained case-control samples with binary responses or quan-
titative responses. The derived equations were validated in a
simulation study, showing that expected values from the equations
and observed values from simulations agreed well. Secondly,
following Daetwyler et al. [12], we derive an expression genomic
prediction accuracy based on the 0,1 observed scale, and
transformed it to that on the liability scale using a liability
threshold model for disease traits in population [13] and in case-
control samples [14]. Compared with Daetwyler et al. [12], our
derivation agrees for population samples, but is more accurate for
case-control samples.
The Genetic Power Calculator [21] is commonly used for
calculation of power is genetic association studies. The calculator is
based on theoretical derivation [22,23] of a single locus model with
required parameters of allele frequency and its effect size (e.g.
relative risk or odds ratio in binary responses). However, our
derivations and application did not require those parameters (see
equation (3), (4) and (8) and Appendix S1 and S2 for application)
because our derivations are based on variance explained by a
locus, and many combinations of allele frequency and effect size
can generate the same variance explained. Our framework easily
accommodates power of association of multiple loci because we
use a single parameter for the total variance that is generated by
any number of loci. Applications of multiple loci association
GWAS have been published recently [24,25]. In practice, the
power to detect causal variants may not exactly agree with our
analytical derivations because of unknown parameters such as
linkage disequilibrium among variants and distribution of effect
size that alter the effective number of tests. We recommend that
such unknown parameters should be carefully considered in
applying power calculation.
Recently, Dudbridge [11] proposed a comprehensive study
about power and predictive accuracy of polygenic scores. Our
equation (11) and Dudbridge’s equation (13) [11] are analogous to
each other. However, Dudbridge used his equation (13) with a
heuristic justification from simulations. We analytically derived
equation (11) based on a liability threshold model and gave a
reasonable explanation why fj is approximated as 1.
Lastly, van der Sluis et al. [7] quantified by simulation the
power lost in genetic association analyses of population samples
measured for quantitative endophenotypes but analysed with a
dichotomous case-control score. Our analytical derivations for
such scenarios allow easy generalization of their results to the
design of new studies.
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Appendix S1 R code for the power derivations described in the
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